DKK186.90
1.11% yesterday
Copenhagen, Aug 04, 04:59 pm CET
ISIN
DK0061802139
Symbol
ALK B

ALK-Abelló Stock price

DKK186.90
-2.90 1.53% 1M
+32.20 20.81% 6M
+27.80 17.47% YTD
+42.60 29.52% 1Y
+34.90 22.96% 3Y
+95.90 105.38% 5Y
+145.60 352.54% 10Y
-773.10 80.53% 20Y
Copenhagen, Closing price Mon, Aug 04 2025
-2.10 1.11%
ISIN
DK0061802139
Symbol
ALK B
Industry

Key metrics

Basic
Market capitalization
DKK42.6b
Enterprise Value
DKK42.8b
Net debt
DKK283.0m
Cash
DKK517.0m
Shares outstanding
221.6m
Valuation (TTM | estimate)
P/E
44.7 | 33.9
P/S
7.5 | 6.7
EV/Sales
7.5 | 6.7
EV/FCF
2,380.3
P/B
7.5
Dividends
DPS
DKK0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
DKK5.7b | DKK6.4b
EBITDA
DKK1.5b | DKK1.9b
EBIT
DKK1.2b | DKK1.6b
Net Income
DKK937.0m | DKK1.2b
Free Cash Flow
DKK18.0m
Growth (TTM | estimate)
Revenue
15.5% | 15.2%
EBITDA
51.3% | 63.6%
EBIT
65.0% | 46.1%
Net Income
68.8% | 51.6%
Free Cash Flow
-96.0%
Margin (TTM | estimate)
Gross
64.5%
EBITDA
26.7% | 30.2%
EBIT
21.8%
Net
16.4% | 19.4%
Free Cash Flow
0.3%
Financial Health
Equity Ratio
65.2%
Return on Equity
15.2%
ROCE
18.9%
ROIC
14.8%
Debt/Equity
0.1
More
EPS
DKK4.2
FCF per Share
DKK0.1
Short interest
-
Employees
3k
Rev per Employee
DKK2.0m
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a ALK-Abelló forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a ALK-Abelló forecast:

Buy
86%
Hold
14%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5,708 5,708
16% 16%
100%
- Direct Costs 2,029 2,029
12% 12%
36%
3,679 3,679
18% 18%
64%
- Selling and Administrative Expenses 1,907 1,907
7% 7%
33%
- Research and Development Expense 530 530
10% 10%
9%
1,521 1,521
51% 51%
27%
- Depreciation and Amortization 277 277
10% 10%
5%
EBIT (Operating Income) EBIT 1,244 1,244
65% 65%
22%
Net Profit 937 937
69% 69%
16%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,753
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today